Neuromuscular junction destruction during amyotrophic lateral sclerosis: insights from transgenic models.

Amyotrophic lateral sclerosis (ALS) represents the major adult-onset motor neuron disease. Analyses of ALS animal models have shown that motor neuron death starts with neuromuscular junction (NMJ) destruction and distal axonal degeneration. Most importantly, motor neuron death results from pathological events occurring outside the motor neuron, especially in glial cells and skeletal muscle and, surprisingly, is associated with pathological defects outside the motor system. In particular, ALS pathogenesis includes systemic defects such as muscle hypermetabolism, energy deficit, and widespread alterations of lipid metabolism that were shown to participate in motor neuron degeneration. Current research should now focus on understanding the relationships between these pathological hallmarks and how such global defects lead to the ALS-linked selective loss of motor neurons.

[1]  M. Mattson,et al.  Energy intake and amyotrophic lateral sclerosis , 2007, NeuroMolecular Medicine.

[2]  A. Echaniz-Laguna,et al.  Sodium Valproate Exerts Neuroprotective Effects In Vivo through CREB-Binding Protein-Dependent Mechanisms But Does Not Improve Survival in an Amyotrophic Lateral Sclerosis Mouse Model , 2007, The Journal of Neuroscience.

[3]  J. Morrison,et al.  Transgenic mice expressing an altered murine superoxide dismutase gene provide an animal model of amyotrophic lateral sclerosis. , 1995, Proceedings of the National Academy of Sciences of the United States of America.

[4]  V. Meininger,et al.  Increased peripheral lipid clearance in an animal model of amyotrophic lateral sclerosiss⃞ Published, JLR Papers in Press, April 16, 2007. , 2007, Journal of Lipid Research.

[5]  L. Barbeito,et al.  Increased glutathione biosynthesis by Nrf2 activation in astrocytes prevents p75NTR‐dependent motor neuron apoptosis , 2006, Journal of neurochemistry.

[6]  P. Caroni,et al.  Accumulation of SOD1 Mutants in Postnatal Motoneurons Does Not Cause Motoneuron Pathology or Motoneuron Disease , 2002, The Journal of Neuroscience.

[7]  M. Benatar Lost in translation: Treatment trials in the SOD1 mouse and in human ALS , 2007, Neurobiology of Disease.

[8]  J. Hauw,et al.  Muscle Nogo‐a expression is a prognostic marker in lower motor neuron syndromes , 2007, Annals of neurology.

[9]  P. Aebischer,et al.  Systemic AAV6 delivery mediating RNA interference against SOD1: neuromuscular transduction does not alter disease progression in fALS mice. , 2008, Molecular therapy : the journal of the American Society of Gene Therapy.

[10]  Minh N. H. Nguyen,et al.  Wild-Type Nonneuronal Cells Extend Survival of SOD1 Mutant Motor Neurons in ALS Mice , 2003, Science.

[11]  Hynek Wichterle,et al.  Astrocytes expressing ALS-linked mutated SOD1 release factors selectively toxic to motor neurons , 2007, Nature Neuroscience.

[12]  A. Pramatarova,et al.  Neuron-Specific Expression of Mutant Superoxide Dismutase 1 in Transgenic Mice Does Not Lead to Motor Impairment , 2001, The Journal of Neuroscience.

[13]  J. Loeffler,et al.  Evidence for defective energy homeostasis in amyotrophic lateral sclerosis: benefit of a high-energy diet in a transgenic mouse model. , 2004, Proceedings of the National Academy of Sciences of the United States of America.

[14]  A. Musarò,et al.  Muscle expression of a local Igf-1 isoform protects motor neurons in an ALS mouse model , 2005, The Journal of cell biology.

[15]  J. E. Kranz,et al.  Design, power, and interpretation of studies in the standard murine model of ALS , 2008, Amyotrophic lateral sclerosis : official publication of the World Federation of Neurology Research Group on Motor Neuron Diseases.

[16]  G. Kollias,et al.  Onset and Progression in Inherited ALS Determined by Motor Neurons and Microglia , 2006, Science.

[17]  D. Gutmann,et al.  Astrocytes as determinants of disease progression in inherited amyotrophic lateral sclerosis , 2008, Nature Neuroscience.

[18]  A. Musarò,et al.  Skeletal muscle is a primary target of SOD1G93A-mediated toxicity. , 2008, Cell metabolism.

[19]  M. Schwab,et al.  The neurite outgrowth inhibitor Nogo‐A promotes denervation in an amyotrophic lateral sclerosis model , 2006, EMBO reports.

[20]  F. Gage,et al.  Gene transfer demonstrates that muscle is not a primary target for non-cell-autonomous toxicity in familial amyotrophic lateral sclerosis , 2006, Proceedings of the National Academy of Sciences.

[21]  Maarten Dewil,et al.  Inhibition of p38 mitogen activated protein kinase activation and mutant SOD1G93A-induced motor neuron death , 2007, Neurobiology of Disease.

[22]  J. Hauw,et al.  Nogo expression in muscle correlates with amyotrophic lateral sclerosis severity , 2005, Annals of neurology.

[23]  S. Mckercher,et al.  Wild-type microglia extend survival in PU.1 knockout mice with familial amyotrophic lateral sclerosis , 2006, Proceedings of the National Academy of Sciences.

[24]  Guy A Rouleau,et al.  Genetics of familial and sporadic amyotrophic lateral sclerosis. , 2006, Biochimica et biophysica acta.

[25]  R. Oppenheim,et al.  Complete Dissociation of Motor Neuron Death from Motor Dysfunction by Bax Deletion in a Mouse Model of ALS , 2006, The Journal of Neuroscience.

[26]  V. Meininger,et al.  Amyotrophic lateral sclerosis: all roads lead to Rome , 2007, Journal of neurochemistry.

[27]  V. Meininger,et al.  Nogo Provides a Molecular Marker for Diagnosis of Amyotrophic Lateral Sclerosis , 2002, Neurobiology of Disease.

[28]  C. Hoogenraad,et al.  Neuron-Specific Expression of Mutant Superoxide Dismutase Is Sufficient to Induce Amyotrophic Lateral Sclerosis in Transgenic Mice , 2008, The Journal of Neuroscience.

[29]  J. Holstege,et al.  Human Cu/Zn Superoxide Dismutase (SOD1) Overexpression in Mice Causes Mitochondrial Vacuolization, Axonal Degeneration, and Premature Motoneuron Death and Accelerates Motoneuron Disease in Mice Expressing a Familial Amyotrophic Lateral Sclerosis Mutant SOD1 , 2000, Neurobiology of Disease.

[30]  C. Guégan,et al.  Programmed cell death in amyotrophic lateral sclerosis. , 2003, The Journal of clinical investigation.

[31]  J. Glass,et al.  Amyotrophic lateral sclerosis is a distal axonopathy: evidence in mice and man , 2004, Experimental Neurology.

[32]  V. Meininger,et al.  Guidelines for the preclinical in vivo evaluation of pharmacological active drugs for ALS/MND: Report on the 142nd ENMC international workshop , 2007, Amyotrophic lateral sclerosis : official publication of the World Federation of Neurology Research Group on Motor Neuron Diseases.

[33]  M. Gurney,et al.  Motor neuron degeneration in mice that express a human Cu,Zn superoxide dismutase mutation. , 1994, Science.

[34]  J. Haines,et al.  Mutations in Cu/Zn superoxide dismutase gene are associated with familial amyotrophic lateral sclerosis , 1993, Nature.

[35]  Kevin Eggan,et al.  Non–cell autonomous effect of glia on motor neurons in an embryonic stem cell–based ALS model , 2007, Nature Neuroscience.

[36]  D. Cleveland,et al.  ALS: A Disease of Motor Neurons and Their Nonneuronal Neighbors , 2006, Neuron.